Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
11 "Jin Sil Seong"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
Efficacy of Postoperative Concurrent Chemoradiation for Resectable Rectal Cancer: A Single Institute Experience
Joong Bae Ahn, Hee Chul Chung, Nae Choon Yoo, Jae Kyung Roh, Nam Kyu Kim, Chang Ok Suh, Gwi Eon Kim, Jin Sil Seong, Woong Ho Shim, Hyun Cheol Chung
Cancer Res Treat. 2004;36(4):228-234.   Published online August 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.4.228
AbstractAbstract PDFPubReaderePub
Purpose

For patients with Dukes' stage B and C rectal cancer, surgery followed by adjuvant chemoradiotherapy is considered to be the standard treatment. However, the drugs used in combination with 5-fluorouracil (5-FU), the method of administration, duration of adjuvant therapy and the frequencies of administration presently remain controversial topics. We investigated (1) the efficacy and safety of adjuvant radiotherapy and 5-FU/leucovorin (LV) chemotherapy for patients who had undergone curative resection and (2) the effect of dose related factors of 5-FU on survival.

Materials and Methods

130 rectal cancer patients with Dukes' B or C stage disease who were treated with curative resection were evaluated. The adjuvant therapy consisted of two cycles of 5-FU/LV chemotherapy followed by pelvic radiotherapy with chemotherapy, and then 4~10 more cycles of the same chemotherapy regimen were delivered based on the disease stage. The cumulative dose of 5-FU per body square meter (BSA), actual dose intensity and relative dose intensity were obtained. The patients were divided into two groups according to the median value of each factor, and the patients' survival rates were compared.

Results

With a median follow-up duration of 52 months, the 5-year disease-free survival and overall survival rates of 130 patients were 57% and 73%, respectively. Locoregional failure occurred in 17 (13%) of the 130 patients, and the distant failure rate was 27% (35/130). The chemotherapy related morbidity was minimal, and there was no mortality for these patients. The cumulative dose of 5-FU/BSA had a significant effect on the 5-year overall survival for Dukes' C rectal cancer patients (p=0.03). Multivariate analysis demonstrated that only the performance status affected the 5-year overall survival (p=0.003).

Conclusion

An adjuvant therapy of radiotherapy and 5-FU/LV chemotherapy is effective and tolerable for Dukes' B and C rectal cancer patients. A prospective, multicenter, randomized study to evaluate the effects of the cumulative dose of 5-FU/BSA on survival is required.

Citations

Citations to this article as recorded by  
  • Seven low-mass ions in pretreatment serum as potential predictive markers of the chemoradiotherapy response of rectal cancer
    Kangsan Roh, Seung-Gu Yeo, Byong Chul Yoo, Kyung-Hee Kim, Sun Young Kim, Min-Jeong Kim
    Anti-Cancer Drugs.2016; 27(8): 787.     CrossRef
  • A 19-Gene expression signature as a predictor of survival in colorectal cancer
    Nurul Ainin Abdul Aziz, Norfilza M. Mokhtar, Roslan Harun, Md Manir Hossain Mollah, Isa Mohamed Rose, Ismail Sagap, Azmi Mohd Tamil, Wan Zurinah Wan Ngah, Rahman Jamal
    BMC Medical Genomics.2016;[Epub]     CrossRef
  • Safety of Early Chemotherapy after a Laparoscopic Colorectal Cancer Resection: A Case-Control Study
    Seung Ho Shin, Sun-Il Lee, Dong-Jin Choi, Si-Uk Woo, Jin Kim, Byung-Wook Min, Hong-Young Moon, Seon Hahn Kim
    Journal of the Korean Society of Coloproctology.2009; 25(6): 429.     CrossRef
  • 9,011 View
  • 51 Download
  • 3 Crossref
Close layer
Effecacy of Induction chomotherapy in Squamous Cell Carcinoma of the Head and Neck
Joo Hang Kim, Byung Soo Kim, Eun Hee Koh, Yi Hyeong Lee, Gwi Eon Kim, Chang Ok Suh, Won Yong Oh, Kwan Ho Cho, Jin Sil Seong, Won Pyo Hong, Myung Hyun Chung, Won Sang Lee, Cheong Soo Park, Choong Koo
J Korean Cancer Assoc. 1985;17(1):28-34.
AbstractAbstract PDF
A clinical study was carried out to investigate the effectiveness and feasjbility of one course of induction chemotherapy with cis-platinum, vincriatine, and bleomycin in 40 patients with squamous cell carcinoma of the head and neck. Twenty three patients(57.5%) had an objective responses; there were 1 complete response (2.5%) and 22 partial responses(55.0%). Responses to chemotherapy was not significantly influenced by disease stage and there were insufficient numbers for a site-by-site comparison. Drug toxicity was tolerable with no life threatening side effects and no added risks to surgery or radiotherapy were encountered. We concluded the effectiveness and feasibility of induction chemotherapy were estabilished.
  • 3,074 View
  • 13 Download
Close layer
The Treatment Results of Non - Metastatic Wilms'tumor by Multimodality Approach
Jin Sil Seong, John J. K. Loh, Chang Ok Suh, Gwi Eon Kim, H. J. Chung, I. J. Choi, Byung Soo Kim
J Korean Cancer Assoc. 1988;20(1):59-67.
AbstractAbstract PDF
Forty-two cases of non-metastatic Wilms tumor, treated at Dept. of Radiation Oncology, Yonsei University College of Medicine, Yonsei Cancer Center, between January 1970 and September 1984 were retrospectively analysed. With the introduction of well-planned multimodality concept, 26 patients were treated in this manner (group A), and multimodality treatment consist of surgery, radiotherapy, and chemotherapy and details of treatment regimen are described. Prior to introduction of multimodality concept, 16 patients were treated by rather individual basis with diversities of multimodalities which was not well-planned (group B). Two year relapse free survival rate of group A and group B was 88% and 31%, respectively (p< 0.05). By stage in group A, 2 yr. RFS for stage I, II, and III showed 92%, 88%, and 80%, respectively. The most significant prognostic factor was histologic subtype, i.e., favorable vs, unfavorable histology (p<0.005). Other prognostic factors included weight of tumor mass and status of lymph node involvement (p<0.05). From this study it can be concluded that; 1. well-planned multimodality approach to Wilms tumor can produce far superior survival relative to that of not well planned, 2. similar good results can also applied to even in the advanced stage, 3. significant prognostic factors are histologic subtype, weight of tumor mass, and status of lymph node involvement.
  • 2,526 View
  • 13 Download
Close layer
Effect of Radiofrequency Hyperthermia on Hepatocellular Carcinoma - Preliminary report -
Chang Ok Suh, John J. K. Loh, Jin Sil Seong, Jae Kyung Roh, Byung Soo Kim, In Suh Park, Heung Jae Choi
J Korean Cancer Assoc. 1988;20(2):117-126.
AbstractAbstract PDF
Effectiveness of hyperthermia in the treatment of hepatocellular carcinoma was evaluated by the restrospective analysis of 31 patients who received radiofrequency hyperthermia at Department of Radiation Oncology, Yonsei Cancer Center, Yonsei Univ. College of Medicine between May 1985 and March 198B. All patients had advanced unresectable tumors, either unsuitable or re,fractory to conventional treatment modalities. B MHz radiofrequency capacitive type of hyperthermia was used either alone (1 case) or combined with other treatment modalities; i.e. 16 cases with external radiation, 7 cases with chemotherapy, 4 cases with l-131 Lipoidol and 3 cases with external radiation+ chemotherapy. Hyperthermia was given once or twice a week, usually 30 minutes after radiotherapy or chemotherapy. External radiotherapy was given with an average dose of 2,500-3000 cGy in 3 weeks. Response rate (CR! PR+ MR) was 32.3% (10/31); CR was achieved in one patient, PRa in 2 cases, PRb in 4 cases, and MR in 3 cases. All responders except for one received external radiotherapy with hyperthermia. Response rate of the patients who received combined radiotherapy and hyperth- ermia was 47.4% (9/19). On the other hand, only one of tweleve patients who received combination of hyperthermia and chemotherapy or I-131-Lipiodol showed partial response. As a result, hyperthermia was more effective when combined with external radiation than when combining with chemotherapy or other modality. In conclusion, hyperthermia, combined with external radiotherapy, is promising treatment method in the management of unresectable hepatocelluar carcinomas.
  • 2,455 View
  • 22 Download
Close layer
Combined Radiotherapy and Hyperthermia for Locally Advanced Cervical Carcinoma
John Juhn Kyu Loh, Jin Sil Seong, Chang Ok Suh, Gwi Eon Kim, Byung Soo Kim, Jae Wook Kim, Tchan Kyu Park
J Korean Cancer Assoc. 1988;20(2):172-180.
AbstractAbstract PDF
Twenty-one patients with locally advanced cervical carcinoma, who all thought to refractory to conventional treatment modality, i.e., mass size above 5 cm in shortest diameter and/or had poor response to radiotherapy at the dose of 3000 cGy/3 wk, treated with combined radiotherapy and hyperthermia between May 1985 and December 1987, at the Dept. of Radiation Oncology, Yonsei University College of Medicine, Yonsei Cancer Center, were retrospectively analysed. 8 MHz radiofrequency capacitive type of hyperthermia was combined with radiotherapy in 21 patients. Extemal radiothcrapy with a total dose of 4500-6000 cGy/4-6 wk and high dose rate ICR with a total dose 3000-390(l cGy in 10-13 fractions/4 wks were given. Hyperthermia was given twice a week with a total of 4 10 treatment sessions. In all cases hyperthermia was given within 30 minutes after radiotherapy. Temperature was measured by inserting thermocouple through the vaginal fornix and an attempt was made to maintain 40C or above for at least 30 minutes. As a result, CR was achived in 15 patients(17%), and PR in 6 patients. The overall response rate was 100%. Side effects were 1 case of pelvic abscess, 2 second degree burn, and 4 fat necrosis, and prognostic factors associated with tumor response.
  • 2,351 View
  • 17 Download
Close layer
Combined Hyperthermia and Radiation Therapy on Primary Hepatocellular Carcinoma
Jin Sil Seong, Yun Ku Lee, Chang Ok Suh, John Juhn Kyu Loh, Hyung Sik Yoo, Jae Kyung Roh, Byung Soo Kim, Kwang Hyub Hahn, Sang In Lee, Heung Jae Choi
J Korean Cancer Assoc. 1989;21(1):117-129.
AbstractAbstract PDF
Thirty patients with unresectable hepatocellular carcinoma due to either locally advanced lesion or association with liver cirrhosis, treated with combined hyperthermia and radiotherapy between April 1988 and July 1988, at Dept. of Radiation Oncology, Yonsei University College of Medicine, were prospectively ananlysed. External radiotherapy of a total dose of 3060 cGy/3.5 wks was given. Hyperthermia was given twice a week with a total of 6 treatment sessions using 8 MHz radiofrequency capacitive type heating device, i.e., Thermotron RF-8 and Cancermia. In all cases hyperthermia was given within 30 minutes after radiotherapy. Temperature was measured by inserting thermocouple into the tumor mass under the ultrasonographic guidance in all patients except for those who had bleeding tendency. As a result, PR was achieved in 12 patients (40%) and symptomatic improvement was observed in 22 patients (78. 6%) among 2S patients who had suffered from abdominal pain. The most significant factor affecting tumor responae rate was the type of tumor (single massive; 10/14, 71.4%, diffuse infiltrative; 2/10, 20%, multinodular; 0/6, 0%, P< 0.005>. There were not any significant side effects relating to combined treatment. Hepatic failure was the leading cause of death (5/11, 45.5%) and distant metastases were observed in 5 patients (one to brain, four to lung). In conclusion, combined hyperthermia and radiotherapy can be considered as an effective treatment modality in management of primary hepatocellular carcinoma.
  • 2,469 View
  • 20 Download
Close layer
Recurrent Wilms' Tumor Following Primary Treatment
Jin Sil Seong, Chang Ok Suh, Gwi Eon Kim, Byung Soo Kim, John Juhn Kyu Loh
J Korean Cancer Assoc. 1989;21(2):424-431.
AbstractAbstract PDF
Fourteen cases of recurrent Wilms' tumor following primary treatment, treated at Dept. of Radiation Oncology, Yonsei Vniversity College of Medicine, Yonsei Cancer Center between 1970 and 1984 were retrospectively analysed. All the patients relapsed within 2 years and the most frequently involved site appeared the lung followed by the primary site and the liver. Among 7 patients to whom salvage treatment was attempted, 3 were successfully salvaged to long term survival over 3 years. From this study it can be concluded that the close follow up to detect any recurrent disease as soon as possible should be done, salvage treatment should be tried with more refined treatment regimen, and new attempts, although experimental, should also be done to the patients who show poor response to conventional salvage treatment.
  • 2,080 View
  • 14 Download
Close layer
Assessment of Cell Proliferation in Primary and Recurrent Colorectal Cancers - Expression of Transforming Growth Factor - α and Prolifer
Jin Sil Seong, Sun Hee Sung, Jung Woon Lee, Hyun Soo Shin, Charn Il Park, Oh Hun Kwon
J Korean Cancer Assoc. 1995;27(2):223-230.
AbstractAbstract PDF
Cell proliferation potential has been found to be a significant biological parameter correlated with the clinical outcome. This study was ta investigate the cell proliferation potential in primary and recurrent colorectal tumor tissues. Using paraffin-embedded tissues from the paired primary and recurrent tumors of l0 patients, a simple hematoxylineosin stain was done and immunohistochemical stains for trans- forming growth factor-a(TGF-a) and proliferating cell nuclear antigen(PCNA) were performed through a labeled streptavidine biotin method. DNA contents and S-phase fraction(SPF) of the cells were assessed by flowcytometric DNA analysis. The degree of differentiation was poorer in the recurrent tumors than in primary tumors. In 4 primary tumors with mixed adenocacinoma and mucinous adenocarcinoma, only the mucinous adenocarcinoma companent was shown in the recurrent tumors. There was no difference in TGF-a expression between the primary and the recurrent tumors however, PCNA was overexpressed in the recurrent tumors comparing to the primary tumors. Flow cytometric DNA analysis was successful in 7 paired cases. There was change of the ploidy from the diploidy to the aneuploidy in 4 cases. SPF showed remarkable increase in the recurrent tumors comparing to the primary tumors. These results show high proliferative potential of the recurrent colorectal tumors, which can be measured using PCNA expression and SPF as biomarkers. Based on the results of this study, an effort to establish more refined method to predict recurrence should be pursued.
  • 2,272 View
  • 12 Download
Close layer
Expression and Significance of c-erbB-2 in Radically Resected Colorectal Cancer
Hyun Cheol Chung, Sun Young Rha, Joon Oh Park, Seung Hun Song, Jae Yong Cho, Jung Bae Aha, Hye Ran Lee, Chong In Lee, Nae Choon Yoo, Joo Hang Kim, Jae Kyung Roh, Jin Sil Seong, Gwi Eon Kim, Jin Sik M
J Korean Cancer Assoc. 1995;27(3):389-403.
AbstractAbstract PDF
Overexpression of c-erbB-2 oncoprotein has been shown to correlate with poor prognosis and drug-resistance to the conventional chemotherapy with 5-fluorouracil in breast and gastric cancers. To evaluate the clinical significance of c-erbB-2 overexpreseion in colorectal cancer, immunohistochemical staining was performed with the paraffin-embedded tiasues of 141 colorectal cancer patients with curative surgery. The follow-up duration ranged from 7 to 61 months(median 30 months). Two-year disease- free and overall survival rate of the total patients were 77%, 91%, respectively. The c-erbB-2 positive rate was 24.8%, Even if patients with c-erbB-2 overexpression showed a tendency of poor prognosis than c-erbB-2 negative patients, T-factor and the TNM stage were independent prognostic factors in multivariate analysis. In subset analysis with c-erbB-2 negative patienta, there were no differences in recurrence rate and 2-year disease-free survival rate between pa- tients with chemotherapy and without chemotherapy(20.0% versus 26.1%)(80.0% versus 82.0%). However, in c-erbB-2 positive patients, those subgroup with chemotherapy showed tendencies toward advantages in relapse rate and 2-year disease-free survival rate than those of subgroup without chemotherapy(21.0% versus 50.0%; p=0.09)(76.0% versus 50.0%: p=0.06). Also, there was a tendency of increased time to relapse in patients with chemotherapy comparing to that of the patients without chemotherapy(7.5 months versus l7.0 months; p = 0.09). In stage III, patients with c-erbB-2 overexpression showed increased 2-year disease-free survival rate with chemotherapy as comparing to that of patients without chemotherapy(81.0% versus 29.0%; p= 0.003). Again, this survival benefit was not found in c-erbB-2 negative stage III patients regard- less of chemotherapy. In conclusion, c-erbB-2 overexyression might be a marker of relative drug resistance to 5-FU which will be converted with the high dose treatment of modulation with leucovorin. A prospective randomized trial is warrented to confirm this suggestion and for the clinical applica- tion of c-erbB-2 overexpression.
  • 2,722 View
  • 12 Download
Close layer
Cell Kinetics Studies of Human Epithelial Cancers with Bromodeoxyuridine Labeling
Jin Sil Seong, Jung Woon Lee, Eun Ji Chung, Yung Tae Kim, Jae Wook Kim, Nam Kyu Kim, Sung Joon Hong, Eun Chan Choi, Won Sang Lee, Oh Hun Kwon, Gwi Eon Kim
J Korean Cancer Assoc. 1995;27(5):783-790.
AbstractAbstract PDF
Cell kinetic parameters of labeling index (LI), duration of S-phase (Ts), and potential doubling time (Tpot) were analyzed following infusion of bromodeoxyuridine (BUdR) in 33 patients with various epithelial cancers. Twelve uterine cervical cancers, 9 rectal cancers, 7 head and neck caneers, and 5 bladder cancers were included. Biopsies were taken about 4-6 h after 200 mg/m(2) BUdR infusion and the samples were anaiyzed with bivariate DNA /BUdR flow cytometry. The distribution of cell kinetic parameters for the 33 epithelial cancers showed a large range of values for each parameter. The median LI, Ts, and Tpot were 4.5%, 10.8 h, and 242.3 h, respectively. Eight among 33 patients (24.2%) showed aneuploidy. In aneuploid tumors the distribution of LI, Ts, and Tpot was in relatively small range. Aneupliod tumors appeared to show higher LI and shorter Tpot than those in diploid tumors. In diploid tumors, the poesibility of normal cell contamination could not be ruled out. The results of this study would be a basis for future trial to predict which ones would show tumor clonogen repopulation during radiotherapy so that benefit from altered fractionated radiotherapy.
  • 2,382 View
  • 15 Download
Close layer
Strontium - 89 Treatment for Painful Bone Matastasis
Jin Sil Seong, Jong Doo Lee, Sung Joon Hong, Gwi Eon Kim
J Korean Cancer Assoc. 1995;27(5):797-804.
AbstractAbstract PDF
There are few options for treating painful bone metastasis in multiple sites. Hemibody irradiation, although effective, is limited due to the serious hematologic toxicity. Therefore, use of radiophamaceuticals has been attemyted particularly for the osteoblastic bone metastasis. Strontium-89 (Sr-89) ia a pure beta emitter with its energy 1.4 MeV. It follows the biochemical pathways of calcium and selectively concentrates at the metastatic bone sites with minimai hematologic toxicity. From l993 to 1994, Sr-89 treatment has been performed in 8 patients with painful bone metastaeis from either prostate (6 patients) or breast cancers (2 patients) The patients had the initial level of WBC 3000/L, platelets 100,000/L, and normal renal function. Four mCi(l48 MBq) of Sr-89 was intravenously iniected and the patients were regularly followed with blood cell count test, simple bone x-ray, and radioisotpe bone scan. The changes of subjective pain were scored in 6 patients until the time of this report. Excellent pain relief was achieved in all except 1 patient, who died 1 month after Sr-89 treatment due to advanced disease. Accordingly, the amount of the analgesics intake by the patients showed corresponding decrease. There was slight decrease in the level of WBCs and plateletes at 2-6 weeks after Sr-89 treetment, however those soon recovered with conservative management. Above results show that the Sr-89 treatment can provide effective palliation in petients with painful bone metastasis with acceptable toxicity. However, further study is urgent to establish its indication, timinh and combination with local radiotherapy.
  • 2,663 View
  • 15 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP